EPISODE · Mar 10, 2026 · 1 MIN
Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
from TheBrief.Health · host TheBrief.Health
Long-term levothyroxine therapy in older adults may modestly reduce cardiovascular risk when carefully monitored, but clinicians must balance benefits with risks like atrial fibrillation and bone loss.
What this episode covers
Long-term levothyroxine therapy in older adults may modestly reduce cardiovascular risk when carefully monitored, but clinicians must balance benefits with risks like atrial fibrillation and bone loss.
NOW PLAYING
Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m